79 related articles for article (PubMed ID: 24026733)
21. Lichen sclerosus in a breast cancer survivor.
Moore KA; Potter JE
J Gen Intern Med; 2013 Mar; 28(3):345. PubMed ID: 23288380
[No Abstract] [Full Text] [Related]
22. Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Van Calster B; Van Ginderachter J; Vlasselaer J; Van de Putte G; Berteloot P; Timmerman D; Depypere H; Blomme C; Vlaemynck G; De Jonge E; Van den Broecke R; Vergote I; Amant F; Van Huffel S; Neven P
Menopause; 2011 Feb; 18(2):224-9. PubMed ID: 20881891
[TBL] [Abstract][Full Text] [Related]
23. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Lycette JL; Luoh SW; Beer TM; Deloughery TG
Breast Cancer Res Treat; 2006 Oct; 99(3):249-55. PubMed ID: 16752073
[TBL] [Abstract][Full Text] [Related]
24. What do perceived cognitive problems reflect?
Bender CM; Pacella ML; Sereika SM; Brufsky AM; Vogel VG; Rastogi P; Casillo FE; Richey SM; Ryan CM
J Support Oncol; 2008; 6(5):238-42. PubMed ID: 18551862
[TBL] [Abstract][Full Text] [Related]
25. Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.
Bremec T; Demsar J; Luzar B; Pavlović MD
Dermatol Online J; 2009 Jul; 15(7):14. PubMed ID: 19903442
[TBL] [Abstract][Full Text] [Related]
26. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
27. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
[TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.
Sendur MA; Aksoy S; Zengin N; Altundag K
J BUON; 2013; 18(4):838-44. PubMed ID: 24344006
[TBL] [Abstract][Full Text] [Related]
29. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J
Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664
[TBL] [Abstract][Full Text] [Related]
30. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Bruntsch U
MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
[No Abstract] [Full Text] [Related]
31. [A case of crescentic glomerulonephritis developed under oral anastrozole treatment].
Yoshimoto S; Nakatani K; Maruyama N; Fujiki K; Nakano T; Ueshima K; Fujimoto T; Oka H; Ishikawa H; Inoue F
Gan To Kagaku Ryoho; 2013 Feb; 40(2):267-70. PubMed ID: 23411970
[TBL] [Abstract][Full Text] [Related]
32. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Collins B; Mackenzie J; Stewart A; Bielajew C; Verma S
Psychooncology; 2009 Aug; 18(8):811-21. PubMed ID: 19085975
[TBL] [Abstract][Full Text] [Related]
33. Anastrozole: licence extension. No advantage over tamoxifen in advanced-stage breast cancer.
Prescrire Int; 2001 Jun; 10(53):76-7. PubMed ID: 11718168
[TBL] [Abstract][Full Text] [Related]
34. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Buzdar AU
Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
[TBL] [Abstract][Full Text] [Related]
35. Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
Köberle D; Thürlimann B
Expert Rev Anticancer Ther; 2001 Aug; 1(2):169-76. PubMed ID: 12113022
[TBL] [Abstract][Full Text] [Related]
36. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
37. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
[TBL] [Abstract][Full Text] [Related]
38. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
39. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Nabholtz JM
Oncology; 2006; 70(1):1-12. PubMed ID: 16439860
[TBL] [Abstract][Full Text] [Related]
40. Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer.
Milla-Santos A; Milla L; Calvo N; Portella J; Rallo L; Casanovas JM; Pons M; Rodes J
Anticancer Res; 2004; 24(2C):1315-8. PubMed ID: 15154667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
